FDA advisors unanimously vote to approve Moderna's mRNA after agency drama

Vaccine type and potential advantages

• Thread clarifies this is an mRNA seasonal flu vaccine, not a flu/COVID combo.
• Some expect mRNA to allow faster manufacturing and better strain matching, and potentially broader variant coverage than traditional cultured flu vaccines.
• Others ask whether the main limitation is biological (how many antigens the body can handle at once) versus formulation constraints.

FDA advisory vote, leadership, and governance

• Many see the unanimous advisory vote as a corrective to earlier, controversial FDA actions that blocked or slowed this vaccine.
• A politically appointed FDA leader is heavily criticized as unqualified, politicized, and overruling career scientists; some describe the organizational structure that enables one person to do this as the deeper problem.
• Others defend demands for more rigorous data, arguing that skepticism of industry studies is evidence-based, not political.

Science, truth, and public discourse

• Several comments lament the replacement of scientific expertise with partisan media figures and “hot takes,” seeing it as a broader “subversion of truth.”
• Some argue forums like HN sometimes valorize clever but shallow criticism over deep expertise, contributing to the same cultural problem.

COVID-era policies, trust, and paternalism

• Disagreement over how much pandemic-era government actions eroded trust:
  • One side points to suppression of lab-leak discussion and overconfident public claims as avoidable mistakes that fed distrust.
  • Others view these as minor relative to larger societal harms and emphasize the role of right-wing media in manufacturing distrust.
• Debate over paternalism: some criticize government speech control yet support restrictive actions like blocking vaccines; others note this inconsistency.
• A nutrition site (“realfood.gov”) is cited as an example of paternalistic but broadly accepted public-health messaging.

Individual choice vs centralized regulation

• One view: FDA should generate reliable data, but risk–benefit tradeoffs are inherently subjective and should be left to patients, especially for severe diseases.
• Counterarguments stress that FDA marketing approval decisions do shape life-and-death outcomes by determining which treatments and vaccines are available at all.

Safety, data quality, and conflicts of interest

• Skeptics highlight:
  • Lack of a true placebo control in the flu study.
  • Slightly higher deaths and adverse reactions in the mRNA arm (numbers cited but not contextualized).
  • Industry-funded trials where most authors work for the manufacturer, likened by some to tobacco-funded research.
• Supporters respond that:
  • Industry involvement is inevitable and not automatically fraudulent.
  • mRNA flu vaccines’ theoretical advantages and published trial data (linked in thread) justify cautious optimism.
  • Critics may lack the expertise to properly interpret complex clinical data.

Broader political and social context

• Multiple comments link scientific politicization to broader reactionary or partisan movements; others argue the phenomenon is largely “home-grown” rather than driven mainly by foreign adversaries.
• Personal anecdotes from the pandemic, especially around mask harassment of vulnerable people, are used to illustrate perceived moral failings and harden political positions.